Bleeding Disorders Treatment Market Report 2025

This Bleeding Disorders Treatment market report covers market characteristics, size & growth, segmentation, regional & country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The bleeding disorders treatment market size has grown strongly in recent years. It will grow from $16.95 billion in 2024 to $18.5 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to increased patient awareness, access to healthcare, advancements in hemophilia therapies, global market expansion.

The bleeding disorders treatment market size is expected to see strong growth in the next few years. It will grow to $26.14 billion in 2029 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to aging population, personalized medicine, patient advocacy and support, rise in disposable income, rise in healthcare expenditure. Major trends in the forecast period include personalized treatment plans, expansion of telehealth services, advanced clotting factor therapies, rna-based treatments, access to orphan drug designation.

The growth of the bleeding disorders treatment market is anticipated to be propelled by the increasing number of diagnosed hemophilia patients. Hemophilia, an inherited bleeding disorder characterized by inadequate blood clotting, necessitates replacement therapy for treatment. This involves replacing the deficient blood clotting factors with human plasma concentrates or recombinant forms of clotting factors VIII or IX. In 2021, the World Federation of Hemophilia reported nearly 234,000 confirmed cases of hemophilia worldwide. The escalating number of diagnosed hemophilia patients is a significant driver behind the growth of the bleeding disorders treatment market, emphasizing the importance of advancing treatments for this inherited disorder.

The increasing healthcare expenditure is expected to fuel the growth of the bleeding disorders treatment market in the coming years. Healthcare expenditure refers to the total spending on healthcare costs, encompassing all money allocated to healthcare-related goods and services within a specific healthcare system or economy. This expenditure is vital for supporting the development and accessibility of treatments for bleeding disorders. For example, in October 2024, the Centers for Medicare & Medicaid Services, a US-based federal agency, reported that the health spending share of GDP rose from 17.3 percent in 2022 to 19.7 percent in 2032. Thus, the rise in healthcare expenditure is driving the expansion of the bleeding disorders treatment market.

Major companies in the bleeding disorder treatment market are concentrating on the development of innovative technologies, such as single-dose treatments, to improve treatment efficacy and enhance patient quality of life by reducing the necessity for ongoing therapies. Single-dose treatment refers to a therapeutic strategy that provides a complete treatment with a single administration, aiming for long-lasting effects without the requirement for multiple doses. For example, in June 2023, BioMarin Pharmaceutical Inc., a US-based biotechnology firm, introduced BioMarin's ROCTAVIANTM (valoctocogene roxaparvovec-rvox). ROCTAVIAN is specifically designed for adults with severe hemophilia A (characterized by FVIII activity levels below 1 IU/dL) who do not have pre-existing antibodies to adeno-associated virus serotype 5 (AAV5) as confirmed by an FDA-approved test.

Leading companies in the bleeding disorder treatment market are actively developing on-demand treatments to control bleeding episodes and perioperative management solutions, addressing a broader customer base and aiming to boost sales and revenue. On-demand treatment is a crucial aspect of managing bleeding disorders, empowering individuals to respond promptly to bleeding episodes and ensuring safe perioperative care during surgical procedures. Ongoing advances in clotting factor therapies and treatment strategies are enhancing the overall quality of life for individuals with bleeding disorders, enabling them to lead more active and fulfilling lives. In February 2023, the collaboration between Sanofi and Sobi resulted in the development of the first-in-class, high-sustained factor VIII replacement therapy known as ALTUVIIIO, which received U.S. FDA approval. This groundbreaking medication offers a unique once-a-week dosing schedule, producing factor activity levels above 40% for the majority of the week and significantly reducing bleeding compared to previous factor VIII prophylaxis.

In October 2022, Pfizer Inc., a prominent U.S.-based pharmaceutical and biotechnology corporation, made a strategic move by acquiring Global Blood Therapeutics, Inc. (GBT) for an undisclosed amount. This acquisition was geared towards leveraging GBT's portfolio to expedite discovery processes and provide a range of potential best-in-class medicines for patients with sickle cell disease. Global Blood Therapeutics, Inc., a U.S.-based biopharmaceutical company specializing in the treatment of blood disorders, contributed valuable expertise and products to Pfizer's portfolio, aligning with the broader industry trend of strategic acquisitions to strengthen capabilities and enhance the range of therapeutic offerings in the bleeding disorder treatment market.

Major companies operating in the bleeding disorders treatment market include AbbVie Inc., Bayer AG, Novo Nordisk A/S, Pfizer Inc., Biogen Inc., CSL Behring Company, Grifols SA, Octapharma AG, BDI Pharma Inc., Ferring Pharmaceuticals Ltd., Xenetic Biosciences Inc., Sanofi SA, Alnylam Pharmaceuticals Inc., Novartis AG, Shire plc, Novo Nordisk, Grifols SA, F. Hoffmann-La Roche AG, Sanofi Corporation, Takeda Pharmaceutical Company Limited, Kedrion S.p.A, Biotest AG, LFB S.A, Emergent BioSolutions Inc., Bio Products Laboratory Ltd., HEMA Biologics LLC, ADMA Biologics Inc., Grifols Biologicals Inc., Octapharma Plasma Inc., Kedrion Biopharma Inc., BPL Plasma Inc., BioLife Plasma Services, CSL Plasma Ltd., Grifols Shared Services North America Inc., Octapharma USA Inc., Shire US Inc., Pfizer Canada Inc., Grifols Canada Ltd., Octapharma Canada Inc.

Bleeding disorders constitute a category of medical conditions characterized by inadequate blood clotting, leading to prolonged bleeding following surgery, injury, menstruation, or trauma. The management of these disorders aims to either arrest or diminish the frequency of bleeding episodes.

Key modalities in the treatment of bleeding disorders encompass desmopressin (DDAVP), hormone replacement therapy, contraceptives, anti-fibrinolytic or clot-stabilizing medications, fibrin sealants, drugs for topical application on cuts, and pipeline analysis. Desmopressin (DDAVP) therapies play a pivotal role in diagnosing individuals with mild hemophilia A or von Willebrand disease, effectively halting bleeding. Targeted diseases include hemophilia A, hemophilia B, von Willebrand disease, liver disease, and others. These interventions cater to diverse end users, including hospitals, clinics, specialty clinics, research institutes, and related entities.

The bleeding disorders treatment market research report is one of a series of new reports that provides Bleeding disorders treatment market statistics, including bleeding disorders treatment industry global market size, regional shares, competitors with bleeding disorders treatment market share, detailed Bleeding disorders treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the bleeding disorders treatment industry. This bleeding disorders treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

North America was the largest region in the bleeding disorders treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bleeding disorders treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the bleeding disorders treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The bleeding disorders treatment market includes revenues earned by entities by recombinant coagulation factor concentrates, plasma-derived coagulation factor concentrates. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.